Berger Montague PC Investigates Securities Claims Against LifeMD, Inc. (NASDAQ: LFMD)

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly making materially false and misleading statements regarding its business and financial outlook during the specified class period [1][3]. Company Overview - LifeMD, Inc. is a telehealth provider based in New York, offering direct-to-patient virtual care and pharmacy services [2]. Allegations - The lawsuit claims that LifeMD overstated its competitive position and raised its 2025 guidance without properly accounting for increasing customer acquisition costs, particularly in its RexMD segment and for obesity-related drugs like Wegovy and Zepbound [3]. - Following the revelation of the true facts, LifeMD's shares experienced a significant decline of 44%, equating to a drop of $5.31 per share in a single trading session [3]. Investor Information - Investors who acquired LifeMD securities during the class period have until October 27, 2025, to seek appointment as lead plaintiff representative of the class [2].